Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome. (AML18 Pilot)

This study has been completed.
Leukaemia & Lymphoma Research Group
Experimental Cancer Medicine Centre Network
Information provided by (Responsible Party):
Alan K Burnett, Cardiff University Identifier:
First received: November 5, 2010
Last updated: June 10, 2014
Last verified: June 2014
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2014
  Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)